SEEKING PARTNERS AND INVESTORS

Bantam is seeking partners and funds to initiate Phase 1 first in human and clinical proof of concept studies.

Bantam has raised approximately $25 million from private investors. The company and its current investors are seeking to syndicate a Series B round to:

1) Initiate Phase 1 first in human studies and generate a clinical proof of concept
2) Conduct translational studies to identify and prioritize additional tumor types for clinical development
3) Establish our unique Mechanism of Action as the foundation for a novel drug discovery platform to advance our existing pipeline and discover novel compounds

The above activities offer multiple near-term catalysts, including bringing the company to an exit via partnering event (licensing or acquisition by a Pharma/Biotech company) with a significant investor ROI.

 

Key milestones graphic

KEY INVESTORS

VICTOR KEEN

VICTOR KEEN

  • Practicing attorney 40+ years, currently Counsel at Duane Morris
  • CEO 3DIcon Corp (OTCQB: TDCP) since 2012
  • Former Board Member Research Frontiers (NASDAQ: REFR)
LIONEL GOLDFRANK III

LIONEL GOLDFRANK III

  • Principal in several private investment companies
  • Founder of American & Overseas Asset Services Corporation
  • Formerly with Goldman Sachs
W. JAMES TOZER, JR

W. JAMES TOZER, JR

  • Co-owner and Founder of Vectra Management Group, real estate investment firm.
  • Former Senior Executive Citicorp and President of Prudential Securities
  • Founding Investor in LendingTree, Vectra Bank Colorado, and Draper Bank
  • Bio-Tech Venture Investor in GangaGen, Iveena, PenBlade and PhotoPharmic